(-)-MK 801 maleate

Pricing Availability Delivery Time Qty
Cat.No. 0955 - (-)-MK 801 maleate | C16H15N.C4H4O4 | CAS No. 121917-57-5
Description: NMDA antagonist, less active enantiomer
Chemical Name: (5R,10S)-(-)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cylcohepten-5,10-imine maleate
Purity: ≥99% (HPLC)
Datasheet
Citations (2)
Literature

Biological Activity

Less active enantiomer (10-fold less potent in behavioral studies) than (+)-MK 801 maleate (Cat. No. 0924).

Technical Data

M. Wt 337.37
Formula C16H15N.C4H4O4
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 121917-57-5
PubChem ID 16219612
InChI Key QLTXKCWMEZIHBJ-FWHYOZOBSA-N
Smiles O=C(O)/C=C\C(O)=O.C[C@@]14C3=C(C=CC=C3)C[C@H](N4)C2=C1C=CC=C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
water 8.43 25mM with gentle warming
physiological saline 8.43 25mM with gentle warming

Preparing Stock Solutions

The following data is based on the product molecular weight 337.37. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.96 mL 14.82 mL 29.64 mL
5 mM 0.59 mL 2.96 mL 5.93 mL
10 mM 0.3 mL 1.48 mL 2.96 mL
50 mM 0.06 mL 0.3 mL 0.59 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Genovese and Lu (1991) Effects of MK-801 stereoisomers on schedule-controlled behavior in rats. Psychopharmacology. 105 477 PMID: 1771215

Thompson et al (1990) Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-Methyl-D-aspartate antagonists. J.Med.Chem. 33 789 PMID: 1688947


If you know of a relevant reference for (-)-MK 801 maleate, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: NMDA antagonists Glutamate Receptors N-Methyl-D-Aspartate iGlur Ionotropic (-)-MK801 maleate MK801 NMDA Receptors

2 Citations for (-)-MK 801 maleate

Citations are publications that use Tocris products. Selected citations for (-)-MK 801 maleate include:

Yang et al (2005) Behavioral stress enhances hippocampal CA1 long-term depression through the blockade of the glutamate uptake. J Pharmacol Exp Ther 25 4288 PMID: 15858055

Huang et al (2004) Astrocyte glutamate transporters regulate metabotropic glutamate receptor-mediated excitation of hippocampal interneurons. J Neurosci 24 4551 PMID: 15140926


Do you know of a great paper that uses (-)-MK 801 maleate from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

Neurodegeneration

Neurodegeneration Product Guide

A collection of over 275 products for neurodegeneration research, the guide includes research tools for the study of:

  • Alzheimer's disease
  • Parkinson's disease
  • Huntington's disease
Pain

Pain Research Product Guide

A collection of over 250 products for pain research, the guide includes research tools for the study of:

  • Nociception
  • Ion Channels
  • G-Protein-Coupled Receptors
  • Intracellular Signaling
Alzheimer's

Alzheimer's Poster

Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease

Huntington's Disease Poster

Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Learning & Memory

Learning & Memory Poster

Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.

Pain

Pain Poster

Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Schizophrenia

Schizophrenia Poster

Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster highlights the targets and pathways representing the most promising strategies to pursue for novel drug development.

Pathways for (-)-MK 801 maleate

Protocols

TODO: Add Protocols